postcoital contraceptives การใช้

• "' Clogestone acetate "'( postcoital contraceptive but was never marketed.
• As a postcoital contraceptive, or morning-after pill, tamoxifen was great _ in rats.
• "' Nisterime acetate "'( derivative of dihydrotestosterone ( DHT ) that was developed as a postcoital contraceptive but was never marketed.
• The C17? acetate ester of nisterime, nisterime acetate ( ORF-9326 ), also exists and was developed as a postcoital contraceptive but was similarly never marketed.
• In the 1980s, off-label use of the Yuzpe regimen of certain regular combined oral contraceptive pills superseded off-label use of DES as a postcoital contraceptive.
• Among the services to be offered under the program are postcoital contraceptives, the so-called " morning after " pills, for rape victims and women who have had what organization described as " unprotected, unexpected " sex.
• "' Norethisterone acetate oxime "'( developmental code names "'ORF-5263, So-36 "'), or "'norethindrone acetate oxime "', is a steroidal progestin of the 19-nortestosterone group that was developed as a postcoital contraceptive but was never marketed.
• In 1973, in an attempt to restrict off-label use of DES as a JAMA " ) to emergency situations such as rape, an " FDA Drug Bulletin " was sent to all U . S . physicians and pharmacists that said the FDA had approved, under restricted conditions, postcoital contraceptive use of DES.
• In 1975, the FDA said it had not actually given ( and never did give ) approval to any manufacturer to market DES as a postcoital contraceptive, but would approve that indication for emergency situations such as rape or incest if a manufacturer provided patient labeling and special packaging as set out in a FDA final rule published in 1975.
• To discourage off-label use of DES as a postcoital contraceptive, the FDA in 1975 removed DES 25 mg tablets from the market and ordered the labeling of lower doses ( 5 mg and lower ) of DES still approved for other indications changed to state : " This drug product should not be used as a postcoital contraceptive " in block capital letters on the first line of the physician prescribing information package insert and in a prominent and conspicuous location of the container and carton label.
• To discourage off-label use of DES as a postcoital contraceptive, the FDA in 1975 removed DES 25 mg tablets from the market and ordered the labeling of lower doses ( 5 mg and lower ) of DES still approved for other indications changed to state : " This drug product should not be used as a postcoital contraceptive " in block capital letters on the first line of the physician prescribing information package insert and in a prominent and conspicuous location of the container and carton label.